At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIB ProShares Ultra Nasdaq Biotechnology
Trading 10-20 10:43:17 EDT
107.09
+0.00
0.00%
High107.09Low107.09Vol645.00
Open107.09D1 Closing107.09Amplitude0.00%
Mkt Cap89.95MTradable Cap89.95MTotal Shares840.00K
T/O71.72KT/O Rate0.08%Tradable Shares840.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Merck, 3M Share Gains Contribute to Dow's 238-Point Climb
Dow Jones  ·  59 minutes ago
Merck, 3M Share Gains Contribute to Dow's 238-Point Climb
Amgen's Tezspire Achieves Sustained Remission in Phase 3 Eosinophilic Esophagitis Trial
Reuters  ·  21:09
Amgen's Tezspire Achieves Sustained Remission in Phase 3 Eosinophilic Esophagitis Trial
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and 4D Molecular Therapeutics (FDMT)
TIPRANKS  ·  21:00
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and 4D Molecular Therapeutics (FDMT)
Amgen: Asthma Drug Tezspire Delivered Histologic Remission and Symptom Improvement in Eosinophilic Esophagitis
THOMSON REUTERS  ·  21:00
Amgen: Asthma Drug Tezspire Delivered Histologic Remission and Symptom Improvement in Eosinophilic Esophagitis
Amgen: Statistically Significant Total Endoscopic Remission with no Visible Inflammation or Fibrosis Attained vs Placebo at Week 52
THOMSON REUTERS  ·  21:00
Amgen: Statistically Significant Total Endoscopic Remission with no Visible Inflammation or Fibrosis Attained vs Placebo at Week 52
Amgen: Tezspire 210 Mg & 420 Mg Achieved 64.8% & 68.9% Histologic Remission at Week 24 vs 3.5% Placebo in Crossing Trial
THOMSON REUTERS  ·  21:00
Amgen: Tezspire 210 Mg & 420 Mg Achieved 64.8% & 68.9% Histologic Remission at Week 24 vs 3.5% Placebo in Crossing Trial
AstraZeneca-Amgen Asthma Drug Hits 69% Remission in Esophageal Disease Trial
Reuters  ·  21:00
AstraZeneca-Amgen Asthma Drug Hits 69% Remission in Esophageal Disease Trial
Amgen: Symptom Improvements vs Placebo at Week 24 were Sustained Through Week 52
THOMSON REUTERS  ·  21:00
Amgen: Symptom Improvements vs Placebo at Week 24 were Sustained Through Week 52
Vertex AI and Data Leader Sarah Vlasic Named a 2026 Info-Tech Women Leading IT Award Winner
GlobeNewswire  ·  20:05
Vertex AI and Data Leader Sarah Vlasic Named a 2026 Info-Tech Women Leading IT Award Winner
Analysts Offer Insights on Technology Companies: Coherent Corp (COHR), ServiceNow (NOW) and Vertex (VERX)
TIPRANKS  ·  19:40
Analysts Offer Insights on Technology Companies: Coherent Corp (COHR), ServiceNow (NOW) and Vertex (VERX)
Piper Sandler Remains a Buy on Amgen (AMGN)
TIPRANKS  ·  19:37
Piper Sandler Remains a Buy on Amgen (AMGN)
Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong, Outperforms Competitors
Dow Jones  ·  16:32
Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong, Outperforms Competitors
PRESS Digest -Wall Street Journal - October 20
Reuters  ·  13:03
PRESS Digest -Wall Street Journal - October 20
Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors
Dow Jones  ·  04:34
Gilead Sciences Inc. Stock Underperforms Monday When Compared to Competitors
Moderna Inc. Stock Advances 4.1%, Outperforms Peers
Dow Jones  ·  04:33
Moderna Inc. Stock Advances 4.1%, Outperforms Peers
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
TIPRANKS  ·  10-19 23:19
Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Gilead to present new data across HIV, antiviral research at IDWeek
TIPRANKS  ·  10-19 20:20
Gilead to present new data across HIV, antiviral research at IDWeek
Mattel Names Peter Griffith CFO and Board Director
Reuters  ·  10-19 20:06
Mattel Names Peter Griffith CFO and Board Director
Abivax Shares Fall After Rival Drug Data, Trader Says
Reuters  ·  10-19 19:47
Abivax Shares Fall After Rival Drug Data, Trader Says
Abivax Shares Fall, Last Down 6.8% After Rival Gilead Pill Succeeds in Mid Stage Bowel Disease Trial - Trader
THOMSON REUTERS  ·  10-19 19:01
Abivax Shares Fall, Last Down 6.8% After Rival Gilead Pill Succeeds in Mid Stage Bowel Disease Trial - Trader

Introduction

Company Name.
ProShares Ultra Nasdaq Biotechnology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Issue price:
--